ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1063

Admissions and Readmissions of Patients with Systemic Lupus Erythematosus Is a Major Cause of Direct and Indirect Health Care Costs

Allen P. Anandarajah1, Ugo Awa2, Christine Izzo3, Kate Burns4, Ummara Shah5, Jennifer H. Anolik6 and Christopher T. Ritchlin7, 1Dept of Rheumatology, Univ of Rochester Medical Ctr, Rochester, NY, 2Medicine, University of Rochester Medical Center, Rochester, NY, 3Rheumatology, University of Rochester Medical Center, Rochester, NY, 4Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY, 5Medicine, Strong Memorial Hospital, University of Rochester, Rochester, NY, 6University of Rochester Medical Center, Rochester, NY, 7Allergy, Immunology and Rheumatololgy Division, University of Rochester Medical Center, Rochester, NY

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Cost containment and systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 8, 2015

Title: Systemic Lupus Erythematosus - Clinical Aspects and Treatment II: Patient-Reported Measures, Outcomes and Reporting

Session Type: ACR Concurrent Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose:  Systemic Lupus Erythematosus (SLE), a chronic autoimmune disease that can affect multiple organ systems and is associated with high morbidity. Reports estimate that the cost of direct health care for patients with SLE is 3-fold higher than the national capital average. Limited data are available on the cost of in-patient care for SLE patients.

Objective: To calculate the cost of admissions, rate of readmissions and potential cost of readmissions of SLE patients at a large tertiary care center.

Methods:  We conducted a financial analysis of all admissions for systemic lupus erythematosus at the 2 major hospitals affiliated with the University of Rochester of Medical Center between the July 1st of 2013 and June 30th of 2014. In-patient care for the 2 hospitals, Strong Memorial Hospital (>750 beds) and Highland Community hospital (> 120 beds) are solely provided by faculty in the Department of Allergy, Immunology and Rheumatology.  The total number of admissions for the diagnosis code 710.0 as primary or secondary diagnosis, regardless of rheumatology consults, was calculated. We also estimated the total cost of admissions based on total charges and the revenue generated. Additionally, we recorded the length of stay for all admissions for SLE. To confirm the findings from the financial data search at the two hospitals, we also analyzed our admission log, maintained for all rheumatology consults received for the fiscal year from July 2013 to June 2014, based on primary diagnosis at time of admission and at discharge.

Results:  The total number of SLE admissions for the year was 274, with a total cost estimated to be between $6,213,812.00 and $ 12, 182,166.00 and accounted for 2576 days of admission for all cases. The cost per admission was therefore between $22,678.15 and $ 44,460.46 and the average of length of stay per admission was calculated to be 9.4 days. The cost represented 25.5% of all rheumatology in-patient care. Moreover, 86 SLE consults recorded in the fiscal year 2014, represented about 19% of all in-patient rheumatology admissions, second only to vasculitis as a cause for admission. Of the 86 patients consulted, 12 (14%) were readmitted on multiple occasions accounting for a total of 26 admissions. Readmissions were between 1 and 5 months in duration and were estimated to cost between $317,494.10 and $622,446.44. The most common reason for readmission among these patients was lupus nephritis followed by lupus flare.

Conclusion:  Hospitalization of patients with SLE is a major driver of health care costs and readmission rates for SLE are high. Development of methods to provide coordinated outpatient care and improve outpatient access and counseling are needed to optimize outcomes and decrease cost of care for these patients.


Disclosure: A. P. Anandarajah, None; U. Awa, None; C. Izzo, None; K. Burns, None; U. Shah, None; J. H. Anolik, None; C. T. Ritchlin, AbbVie, 5,Amgen, 5,Novartis Pharmaceutical Corporation, 5,Eli Lilly and Company, 5,Boehringer Ingelheim, 5,Sanofi-Aventis Pharmaceutical, 5,Amgen, 2,AbbVie, 2,UCB Pharma, 2.

To cite this abstract in AMA style:

Anandarajah AP, Awa U, Izzo C, Burns K, Shah U, Anolik JH, Ritchlin CT. Admissions and Readmissions of Patients with Systemic Lupus Erythematosus Is a Major Cause of Direct and Indirect Health Care Costs [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/admissions-and-readmissions-of-patients-with-systemic-lupus-erythematosus-is-a-major-cause-of-direct-and-indirect-health-care-costs/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/admissions-and-readmissions-of-patients-with-systemic-lupus-erythematosus-is-a-major-cause-of-direct-and-indirect-health-care-costs/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology